Financials
Financial year 2025
Worth noting
- Figures corrected afterwards (2021, 2022).
Revenue
€ 7.1 million
▲ 6% vs 2024
Profit
Healthy€ 824,661
▼ 25% vs 2024
Debts
Low€ 4.8 million
▲ 4% vs 2024
KITOZYME from Herstal, company number BE0473676932, closed financial year 2025 with a result of € 824,661 after tax. For that financial year KITOZYME recorded revenue of € 7.1 million and equity of € 17.2 million. Compared with financial year 2024, the result moved from € 1.1 million to € 824,661. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
What happened at KITOZYME?
What happened at KITOZYME in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- P&L EAGLE srl stepped down as director. NBB
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- SPARAXIS SA stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 824,661 (▼ 25% vs 2024). Source: NBB ↗
- Carl MESTDAGH stepped down as director. NBB
- AMNASSEN srl stepped down as director. NBB
- P&L EAGLE srl became a director. NBB
- NOSHAQ PARTNERS SCRL became a director. NBB
In short
From € 4.8 million profit in 2021 to € 824,661 profit in 2025.
Best year ever: 2021, with € 4.8 million profit.
On average € 177,100 of value added per employee in 2025.
A new publication or filing at KITOZYME? We notify you, reason included.
Follow KITOZYMENeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Valois sa (44%), Wallonie Entreprendre sa (18%) and Innode SA (16%). It owns 75.9% of BIOKURIS sa and 20% of KIOMED PHARMA sa itself.
Directors
According to the 2025 annual accounts
Carl MESTDAGH
Chairman of the board
since 2020 · until 2026
since 2025 · until 2027
Director · represented by Benoit FELLIN
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2025 · until 2027
Managing director · represented by François BLONDEL
Also active at: Trafal Belgium, CETIM Student RE
since 2020 · until 2026
Director · represented by Géry LEFEBVRE
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more
since 2025 · until 2027
Shareholders
Participations
75.9%
20%
Establishments
Establishment units
Physical locations of this company
Rue de Milmort 680
4040 Herstal
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Details
- Company number
- 0473.676.932
- VAT number
- BE 0473.676.932
- Registered office
- Rue de Milmort 680, 4040 Herstal
- Names & denominations
- KITOZYME
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 2 January 2001
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Vervaardiging van andere organische chemische basisproducten
Vervaardiging van overige organische chemische basisproducten